SecuritySPRT / support.com, Inc. (86858W101)
Institutional Owners38
Institutional Shares7,665,722 - 40.93%
Common Shares Outstanding18,728,912 shares (as of 2017-12-31)
Institutional Value$ 18,131,000 USD

Institutional Stock Ownership and Shareholders

support.com, Inc. (NASDAQ:SPRT) has 38 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,665,722 shares. Largest shareholders include Fondren Management LP, Renaissance Technologies LLC, VIEX Capital Advisors, LLC, Kennedy Capital Management, Inc., Farwell Grosvenor Nicholas, Vanguard Group Inc, BlackRock Inc., Royce & Associates LLC, Herald Investment Management Ltd, and Geode Capital Management, Llc.
support.com, Inc. (NASDAQ:SPRT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-04-02 SC 13G/A Farwell Grosvenor Nicholas 1,249,000 896,369 -28.23
2018-05-15 13F-HR Bank of New York Mellon Corp 17,520 23,302 33.00 42 64 52.38
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 10,314 10,314 0.00 25 28 12.00
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 3,000 0 -100.00 7 0 -100.00
2018-05-15 13F-HR RBF Capital, LLC 21,949 21,949 0.00 53 58 9.43
2018-02-14 13F-HR MORGAN STANLEY 335 2 -99.40 1 0 -100.00
2018-02-09 13F-HR SMITH, MOORE & CO. 53,590 53,923 0.62 126 130 3.17
2018-05-08 13F-HR THOMPSON SIEGEL & WALMSLEY LLC 2,833 2,833 0.00 7 8 14.29
2018-02-09 13F-HR Royce & Associates LLC 322,366 322,366 0.00 758 780 2.90
2018-05-15 13F-HR UBS Group AG 4,709 5,559 18.05 11 15 36.36
2018-05-15 13F-HR VIEX Capital Advisors, LLC 1,083,531 1,083,531 0.00 2,622 2,991 14.07
2018-02-14 13F-HR STATE STREET CORP 10,105 0 -100.00 22 0 -100.00
2018-02-12 13F-HR Herald Investment Management Ltd 261,072 261,072 0.00 613 626 2.12
2018-05-04 13F-HR ASPIRIANT, LLC 0 20,649 0 57
2018-05-11 13F-HR Gemmer Asset Management LLC 53 53 0.00 0 0
2018-05-15 13F-HR Brandywine Global Investment Management, LLC 5,326 15
2018-05-08 13F-HR Cornerstone Capital, Inc. 60,000 100,266 67.11 145 277 91.03
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 30 30 0.00 0 0
2018-05-15 13F-HR WOLVERINE TRADING, LLC Put 0 12,300 0 34
2018-05-09 13F-HR BlackRock Inc. 485,081 479,299 -1.19 1,174 1,323 12.69
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 32,004 43,632 36.33 77 120 55.84
2018-02-13 13F-HR KENNEDY CAPITAL MANAGEMENT, INC. 923,043 932,067 0.98 2,169 2,256 4.01
2018-05-15 13F-HR Independent Advisor Alliance 14,000 14,000 0.00 36 37 2.78
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 14,413 0 -100.00 35 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 9 0 -100.00 0 0
2018-05-15 13F-HR Fondren Management LP 1,301,874 1,301,874 0.00 3,151 3,593 14.03
2018-05-15 13F-HR DEUTSCHE BANK AG\ 89,598 60,595 -32.37 215 167 -22.33
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 17,725 0 -100.00 43 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 1,115,963 1,156,063 3.59 2,701 3,191 18.14
2018-05-10 13F-HR Spark Investment Management LLC 0 11,600 0 32
2018-05-15 13F-HR JANE STREET GROUP, LLC 10,978 0 -100.00 27 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 105,166 105,166 0.00 255 290 13.73
2018-05-15 13F-HR FIFTH THIRD BANCORP 638 638 0.00 2 2 0.00
2018-02-09 13F-HR Virtu Financial LLC 18,256 44
2018-04-26 13F-HR Lenox Wealth Management, Inc. 1,200 1,200 0.00 3 3 0.00
2018-05-11 13F-HR CITIGROUP INC 139 139 0.00 0 0
2018-05-07 13F-HR Manchester Capital Management LLC 5,000 14
2018-05-09 13F-HR NORTHERN TRUST CORP 52,440 50,344 -4.00 127 139 9.45
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 111,827 111,827 0.00 270 308 14.07
2018-05-11 13F-HR GRT CAPITAL PARTNERS L.L.C. 0 14,000 0 39
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 14,778 10,051 -31.99 36 28 -22.22
2018-05-15 13F-HR VANGUARD GROUP INC 526,711 524,548 -0.41 1,274 1,447 13.58
2018-04-26 13F-HR SIMPLEX TRADING, LLC 0 1,113 0 3
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 0 16,766 0 46

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

15h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

15h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

SA Interview: Special Situation Investing With Antao

2018-05-20 seekingalpha
The two most important factors when evaluating a special situation idea, why there are still opportunities in spin-offs and why your thesis should fit on one page are topics discussed. (7-0)

Support.com: Buy Before It's Too Late

2018-03-05 seekingalpha
Just achieved positive Net Income in the last quarter. Cost-efficient and aligned management. High insider ownership ~15%. (58-3)

CUSIP: 86858W101